Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study

Eur J Clin Invest 2012; 42 (12): 1287–1294 Abstract Background Although visceral obesity, a key abnormality in the metabolic syndrome, is an important risk for cardiovascular diseases, reduction in visceral fat is hard to achieve despite intensive efforts directed at lifestyle modification. The present study was designed to investigate whether ezetimibe, an inhibitor of intestinal cholesterol absorption through its binding to Niemann‐Pick...